

### SAMPLE FLOW CYTOMETRY REPORT

#### INTERPRETATION:

#### INSTITUTION #B05-XXXX

Bone marrow aspirate: Involvement by precursor B-lymphoblastic lymphoma/leukemia (see comments).

#### COMMENT

An abnormal B-lymphoblast population (colored light blue in histograms below) expressing low-intermediate CD19, very low-negative CD45, intermediate CD20, CD22, CD38, HLA-DR, and TdT, bright CD10, variable low CD34, and no surface light chains is identified. The leukemic blasts represent about 15% of the total leukocytes after lysis of the erythroid elements. This finding correlates with the presence of occasional blast-like cells seen on our stained smear of the specimen, although correlation with the bone marrow morphology at the referring institution is also recommended.


#### SPECIMEN INFORMATION:

A1 =B05-XXXX Bone marrow aspirate

#### RECEIVED FOR THE FOLLOWING:

Flow cytometry to rule out persistent pre-B-ALL.

#### RESULTS:



Immunophenotyping by flow cytometry after lysis of the erythroid cells reveals that the white blood cells consist of 84% lymphocytes, 0.8% monocytes, 0.4% maturing granulocytes, and 15% abnormal B-lymphoblasts. The mature lymphocytes consist of 7% B cells (CD19+), 70% T cells (CD3+), and 10% NK cells (CD3-, CD7+). The plasma cells represent 0.3% of the white blood cells.

**ANTIBODIES USED:** CD45, CD19, kappa, lambda, CD10, CD20, CD22, TdT, CD38, CD56, CD5, CD34, CD33, CD38, HLA-DR, CD13

\*\*\*ELECTRONICALLY SIGNED\*\*\*

**Steven J. Kussick, M.D., Ph.D.**  
Hematopathologist

In compliance with CMS regulations, the pathologist's signature on this report indicates that the case has been personally reviewed, and the diagnosis made or confirmed by the Pathologist.